China Medipharm Insights Issue No. 52 - October 2000


USD 1,000.00

* Required Fields

USD 1,000.00


Be the first to review this product

Table of Contents

China Medipharm Insights Issue No. 52 - October 2000, China Medipharm InsightsDRUG CONSUMPTIONDermatological Drug Market AnalysisTraditional Chinese Medicine (TCM) FavoredMarket AnalysisMarket Analysis of Ulcerative Colitis TherapiesPenicillin Prices Trending Upward in China News In BriefGLP-standard Key Lab for New Drug Research Built upChina Makes Breakthrough in Monoclonal Antibody TechnologyHospitals in Changsha Cut Drug PricesHenan Issues Regulations on Medical Service ChargesIncidence of Tuberculosis in Mudanjiang Reaches Record LowGroup Drug Procurement Performs Well in HunanMedical Fees Regarded Too HighDrug Prices Lowered in BeijingMedical Reform Gears up in Jiangsu ProvinceDrug Imports Through Beijing Customs Saw Strong Growth Qingdao Huaren Pharma Allied with Three UniversitiesQingdao Reduced Drug Expenses by Unified Drug ProcurementBreast Cancer Patients in Beijing Tend to Be YoungerMedical Service Charging Standard Adjusted in Shandong ProvinceDemand for County and Village Doctors Met in ChinaPharmaceutical Industry Booming in Zhuhai Special Economic ZoneCompany ProfilesHarbin General Pharma Reports $6.7 Million Net Profit in the First Six MonthsHuadong Pharma Group Acquires Zhejiang Wufeng Pharma Yiwu Huayi Fine Chemicals Co. Joins Hands with Spanish EQ Pharma Shanghai Medicine Group Expands GloballyLivzon Group Sets Up JV in HubeiSino-American Saijin Biopharma EstablishedSino-Cuba Baitai Biopharma EstablishedFuxing Enterprise Plans to List Shanghai Clone on the Hong Kong Stock ExchangeFuxing Enterprise Sets Up an e-Business Website MSD Sponsors Urinary Surgeon Training ProgramDouble Crane Pharma Set Up Subsidiary in AnhuiShanghai First Pharmacy ExpandsTianjin Huajin Pharma BoomingNeptunus Bio Establishes Sales Company Yueyang Zhongxiang Kangshen Pharma Stepped Out Of Loss MakingOne Thousand MT/year Penicillin Project Accomplished in LukangNorth China and Pan Pacific Pharma Jointly Develop New Rheumatoid Arthritis DrugZhaoshang Co. Ltd. Acquired Huaning Biological Product CompanyServier Launches Alvenor into China MarketJilin Dongsheng Pharma EstablishedChongqing Sanxia Invests into Beilu PharmaXi’an Dongsheng Holds Equity Shares in Qinghai PharmaMarket Analysis Market Analysis of Clavulanate Potassium and AmoxicillinConclusionOTC Drug MarketConsumption of OTC Drugs in China HospitalsOther OTCsNew OTC Formulations and Pediatric Drugs Saw Increasing Market Shares in China.Branded Drugs and Joint-Venture-Made Drugs Control Large Market Shares in China.EPO Injection Marketed by North ChinaProduct NewsNew Drugs Released in 2000 China Autumn Drug Trade Fair in GuangzhouCefprozil Launched by Sino-American Shanghai SquibbClass I New Drug ZT-1 To Enter Clinical TrialsBrochodilator Drug Dafulin Marketed by Zhejiang Anglikang PharmaMinulet to Be Marketed in ChinaNew Quinolone Antibiotic Weishaxin Marketed by Shanghai Sunve Chinese-Made Cholera Vaccine Receives Class I NDAQuinolone Antibiotic Nuolisi MarketedAnti-dizziness Drug Yihanning LaunchedSales Rights for Atorvastatin to be AuctionedLevothyroxine Sodium Received NDA and Production PermitShanghai Yanan Wanxiang Launches Anti-acne Drug in BeijingKerman Capsules MarketedCefradine 250mg Capsules Put into Production in Lukang PharmaHangzhou Aoyipollen Launches Glaucoma Drug Nearmox

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.